- Di sistema
- In the last decade, adoptive cell therapies and in particular car t cellshave dramatically changed the therapeutic landscape of hematologicalmalignancies, providing hope where traditional treatments had failed.their progressive expansion into the field of solid tumors confirmsthe extraordinary potential of cellular immunotherapy, yet alsohighlights the many challenges that still need to be addressed.resistance to therapy, tumor escape mechanisms, the hostilemicroenvironment that limits t cell activity, and the persistence oftreatment-related toxicities all represent major obstacles that mustbe overcome in order to fully realize the promise of these revolutionary strategies.